Assessment of the prescription pattern of dydrogesterone in obstetrics and gynaecological disorders in adult women in an outpatient setting across India

Vaneet  Kaur; Pooja Tandon; Shazna Manakkatt Thekke Peedikayil; Sangeetha Damurlolu Ganesh; Sudha Rani; Seema Kakore; Anjali Singh; Suryakant Chawandke; Maneesha Khalse; Reshma Parekar

doi:10.18203/2320-1770.ijrcog20263424

Authors

Vaneet Kaur Department of Department of Obstetrics and Gynaecology, Sapling Hospital for Women and Children, Sarabha Nagar, Ludhiana, Punjab, India
Pooja Tandon Department of Obstetrics and Gynaecology, DMC Hospital, Tagore Nagar, Ludhiana, Punjab, India
Shazna Manakkatt Thekke Peedikayil Department of Obstetrics and Gynaecology, Prime Heal Clinic, Thrikaripur, Kerala, India
Sangeetha Damurlolu Ganesh Department of Obstetrics and Gynaecology, Dhanalakshmi Hospital, Kannur, Kerala, India
Sudha Rani Department of Obstetrics and Gynaecology, Neeraj Multi Speciality Hospital, Baraut, Baghpat, Uttar Pradesh, India
Seema Kakore Department of Obstetrics and Gynaecology, Muslim Library, Main Road, Bhandara, Maharashtra, India
Anjali Singh Department of Obstetrics and Gynaecology, United Medicity Hospital OPD, Jhalwa, Prayagraj (Allahabad), Uttar Pradesh, India
Suryakant Chawandke Department of Gynaecology, Chawandke Hospital, Dr. Lane, Jintur, Maharashtra, India
Maneesha Khalse Medical Affairs, Lupin Limited, Mumbai, Maharashtra, India
Reshma Parekar Medical Affairs, Lupin Limited, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263424

Keywords:

Drug utilisation, Dydrogesterone, Prescription pattern, Real-world evidence

Abstract

Background: Dydrogesterone is a prescribed progestogen used in infertility, threatened abortion, recurrent pregnancy loss, endometriosis, and menstrual disorders. However, large-scale real-world evidence describing its utilisation patterns in clinical practice in India remains limited.

Methods: This multicentric, cross-sectional, observational study included adult women receiving dydrogesterone therapy across India. Data on demographic and reproductive characteristics, clinical indications, comorbidities, treatment regimens, and duration of therapy were collected from routine clinical records and analysed using descriptive and inferential statistics.

Results: A total of 7,160 women were included. Infertility was the most common indication for dydrogesterone therapy (45.0%; n=3219), followed by threatened abortion (27.2%; n=1946) and recurrent pregnancy loss (13.6%; n=972). Dydrogesterone 10 mg twice daily was the most frequently prescribed regimen (49.8%; n=3564), followed by Dydrogesterone 10 mg once daily (30.9%; n=2211) and sustained-release 20 mg once daily (12.4%; n=886). Most patients were aged 18-30 years (73.4%; n=5256), had a normal body mass index (58.9%; n=4218), and were nulligravida (89.3%; n=6394). Significant associations were observed between treatment regimen and clinical indication, age category, body mass index, gravida status, parity status, comorbidity status, and duration of therapy (all p<0.05).

Conclusions: This large multicentric real-world study demonstrates extensive utilisation of dydrogesterone in Indian obstetric and gynaecological practice, with 10 mg twice-daily and once-daily regimens representing the predominant treatment approaches. The findings provide valuable real-world evidence on patient profiles and contemporary prescribing patterns associated with dydrogesterone use in routine clinical care.

References

Patki A. Role of dydrogesterone for luteal phase support in assisted reproduction. Reprod Sci. 2024;31(1):17-29.

Lai TJ, Teng SW, Chang CK, Huang CY. Progesterone in pregnancy: evidence-based strategies to reduce miscarriage and enhance assisted reproductive technology. Med Sci Monit. 2024;30:e943400.

The ESHRE Guideline Group. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009.

National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126). London: NICE; 2021.

Kongwattanakul K, Jatavan P, Musigavong O, Pranpanus S, Salang L, Satirapod C, et al. Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: recommendations by the Thai Interest Group. J Obstet Gynaecol Res. 2025;51(8):e70038.

Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(Suppl 1):S3-11.

Muneeba S, Acharya N, Mohammad S. The role of dydrogesterone in the management of luteal phase defect: a comprehensive review. Cureus. 2023;15(11):e48194.

Stavridis K, Balafoutas D, Kalampokas T, Benetou V, Samoli E, Vlahos N, et al. Oral dydrogesterone versus vaginal progesterone for luteal phase support in frozen-thawed embryo transfer cycles: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2025;14(9):3238.

Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018;109(5):756-62.

Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815-24.

Manickavasagam M, Vakil A, Singh E, Roy H, Lal N, Patel RG, et al. Real-world evidence of dydrogesterone 20 mg and 30 mg sustained-release usage in pregnancy. Cureus. 2024;16(10):e72016.

Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. Fertil Steril. 2017;108(3):393-406.

Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. Fertil Steril. 2017;107(4):840-7.

Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69.

Gajjar H, Banker J, Murarka S, Shah P, Shah N, Bhaskaran L. The impact of progesterone administration routes on endometrial receptivity and clinical outcomes in assisted reproductive technology cycles. Cureus. 2024;16(6):e62571.

Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983-90.

Mitchell JB, Chetty S, Kathrada F. Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety. BMC Womens Health. 2022;22(1):526.

Yasmin A, Roychoudhury S, Sengupta P, Ahmed ABF, Madhu NR, Choudhury AP, et al. Prevalence of polycystic ovary syndrome (PCOS) and its associated hormonal and comorbid risk factors in Northeast India: a cross-sectional comparative study. Ther Adv Reprod Health. 2025; 19:26334941251384195.

Tan J, Yang YY, Yin DY, Xin Q, Ge XC. Research on the impact of thyroid disorders on reproductive function: a narrative review. J Clin Med Res. 2025;17(8):409-22.

Korevaar TIM, Leung AM, Alexander EK, Bliddal S, Boelaert K, Brenta G, et al. American Thyroid Association guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid. 2026;36(4):481-544.